Dr Pusztai is  Professor of Medicine at Yale University, Director of Breast Cancer  Translational Research and Co-Director of the Yale Cancer Center Genomics  Genetics and Epigenetics Program. He is also Chair of the Breast Cancer  Research Committee of the Southwest Oncology Group (SWOG). Dr Pusztai has  made important contributions to establish that estrogen receptor-positive  and-negative breast cancers have fundamentally different molecular, clinical  and epidemiological characteristics. He has been a pioneer in evaluating gene  expression profiling as a diagnostic technology to predict chemotherapy and  endocrine therapy sensitivity and have shown that different biological  processes are involved in determining the prognosis and treatment response in  different breast cancer subtypes. Dr. Pusztai’ s research also clarified the  clinical value of preoperative (neoadjuvant) chemotherapy in different breast  cancer subtypes. With Komen funds, he studies the immune microenvironment of  primary and metastatic breast cancers before and after therapy, and uses that  knowledge to design new treatment strategies for breast cancer.